VBI-2902

VBI-2902
Vaccine description
TargetSARS-CoV-2
Vaccine typeVirus-like particles
Clinical data
Other namesVBI-2902a
Routes of
administration		Intramuscular

VBI-2902 is a COVID-19 vaccine candidate developed by Variation Biotechnologies from the United States.[1]

History

In early 2020, in collaboration with NRC the VBI's vaccine—VBI-2900—was developed. According to the company, they have two vaccine candidates—"enveloped virus-like particle (eVLP)".[2] VBI-2901 is a "trivalent pan-coronavirus vaccine expressing the SARS-CoV-2, SARS-CoV, and MERS-CoV spike proteins". VBI-2902 is a "monovalent COVID-19-specific vaccine expressing the SARS-CoV-2 spike protein".[2] By March 9, the initial Phase 1/2 study of VBI-2902 was underway.[2] VBI received CA$56 million from the federal government towards the COVID-19 vaccine development.[3] The company's CEO, Jeff Baxter, said that VBI-2902 is cheaper to produce than other vaccines.

References

  1. ↑ Philippidis, Alex (1 November 2021). "Six Up-and-Coming COVID-19 Vaccines". GEN - Genetic Engineering and Biotechnology News. Retrieved 23 December 2021.
  2. 1 2 3 "VBI Vaccines Announces Initiation of Enrollment in Adaptive Phase 1/2 Study of Prophylactic COVID-19 Vaccine Candidate, VBI-2902". VBI Vaccines. 9 March 2021. Retrieved 22 March 2021.
  3. ↑ Curran M, Sali D, Kovessy P (August 2020). "Podcast: Kemptville's next boom, Variation Biotechnologies' $56M injection, Vanier 'gateway'" (Podcast). Behind the Headlines. Retrieved 22 March 2021.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.